Unicycive Therapeutics, Inc. (UNCY)

Over the past six months, Unicycive Therapeutics' stock has experienced significant volatility. The stock's 52-week high was $11.00 and its 52-week low was $3.71. As of late March 2026, the share price was around $6.62, representing an increase of 5.60% over the past year and a 45.79% increase over the last six months. Key events impacting the stock price include the FDA acceptance of the OLC NDA resubmission, participation in investor events, and earnings reports.

Information regarding the demand seasonality specifically for Unicycive Therapeutics' products and services is not explicitly available. The company is a clinical-stage biopharmaceutical company, and its lead product, OLC, is still under FDA review for potential approval and launch. Historically, March has been the strongest month for Unicycive Therapeutics' common stock, with an average return of 60.39%, while June tends to be the weakest month, averaging a -21.29% return.

Unicycive Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for kidney diseases. Their business model centers on advancing drug candidates through clinical development and commercialization. Their primary product candidates include Oxylanthanum Carbonate (OLC) / Renazorb, a phosphate binding agent for hyperphosphatemia in CKD patients, and UNI-494, a new chemical entity for acute kidney injury.

Unicycive Therapeutics is headquartered in Los Altos, California, primarily concentrated in the United States. Clinical trials may involve international sites through third-party research organizations, but the company does not report significant owned facilities or commercial operations outside the United States.

Unicycive Therapeutics maintains a reputation as a clinical-stage biotechnology company focused on addressing unmet medical needs in kidney diseases. The company's lead product candidate, oxylanthanum carbonate (OLC), is positioned as a potential next-generation phosphate binder. Analyst sentiment has been generally bullish, with some analysts publishing aggressive upside targets, reflecting the perceived market opportunity and the clear regulatory path for OLC.

Unicycive Therapeutics has a diverse ownership structure. Approximately 32.70% of the company's stock is owned by institutional investors, 21.10% by insiders, and 46.21% by public companies and individual investors. Major institutional owners include Vivo Capital, LLC, and Millennium Management Llc. Shalabh K. Gupta, the Chairman of the Board, President, Chief Executive Officer, and Founder, owns the most shares.